During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in ...

Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and ...

Mark Agulnik, MD, discusses the efficacy and adverse events in the DeFi trial for patients with desmoid tumors given nirogacestat.